drugset / Trial / NCT06037577
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). In this current study, the IP is tested in healthy male volunteers.
Timeline
- Start
- 2019-03-05
- Primary completion
- 2019-05-05
- Completion
- 2019-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM-101 | Monoclonal antibody | 5 mg/kg | Subcutaneous |